Growth Metrics

Merck (MRK) Non Operating Income (2009 - 2026)

Merck (MRK) reported Non Operating Income of -$138.0 million for Q1 2026, down 494.29% year-over-year from $35.0 million in Q1 2025, and up 68.06% on a QoQ basis from -$432.0 million in Q4 2025.

Merck (MRK) has 18 years of Non Operating Income data on file, last reported at -$138.0 million in Q1 2026.

  • Quarterly Non Operating Income fell 494.29% year-over-year to -$138.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$325.0 million (down 1260.71% YoY) and the FY2025 annual result came in at -$151.0 million, down 729.17% from the prior year.
  • Non Operating Income grew to -$138.0 million in Q1 2026 per MRK's latest filing, from -$432.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $238.0 million in Q3 2025 and bottomed at -$708.0 million in Q1 2022.
  • The 5-year median for Non Operating Income is -$89.0 million (2023), against an average of -$131.1 million.
  • The widest annual swing landed in 2022, when Non Operating Income tumbled 525.24%; it then surged 228.57% in 2024.
  • Tracing MRK's Non Operating Income over 5 years: stood at $75.0 million in 2022, then tumbled by 204.0% to -$78.0 million in 2023, then plunged by 62.82% to -$127.0 million in 2024, then plunged by 240.16% to -$432.0 million in 2025, then jumped by 68.06% to -$138.0 million in 2026.
  • Per Business Quant, the three latest MRK Non Operating Income figures stand at -$138.0 million (Q1 2026), -$432.0 million (Q4 2025), and $238.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -65.00 Mn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -294.00 Mn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -2.31 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -138.00 Mn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 75.00 Mn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 235.00 Mn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -861.00 Mn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -32.00 Mn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -138.00 Mn
Dec 31, 2025 -432.00 Mn
Sep 30, 2025 238.00 Mn
Jun 30, 2025 7.00 Mn
Mar 31, 2025 35.00 Mn
Dec 31, 2024 -127.00 Mn
Sep 30, 2024 162.00 Mn
Jun 30, 2024 -42.00 Mn
Mar 31, 2024 33.00 Mn
Dec 31, 2023 -78.00 Mn
Sep 30, 2023 -126.00 Mn
Jun 30, 2023 -172.00 Mn
Mar 31, 2023 -89.00 Mn
Dec 31, 2022 75.00 Mn
Sep 30, 2022 -429.00 Mn
Jun 30, 2022 -438.00 Mn
Mar 31, 2022 -708.00 Mn
Dec 31, 2021 334.00 Mn
Sep 30, 2021 450.00 Mn
Jun 30, 2021 103.00 Mn
Mar 31, 2021 455.00 Mn
Dec 31, 2020 253.00 Mn
Sep 30, 2020 312.00 Mn
Jun 30, 2020 387.00 Mn
Mar 31, 2020 -71.00 Mn
Dec 31, 2019 233.00 Mn
Sep 30, 2019 -35.00 Mn
Jun 30, 2019 -140.00 Mn
Mar 31, 2019 -188.00 Mn
Dec 31, 2018 -110.00 Mn
Sep 30, 2018 172.00 Mn
Jun 30, 2018 48.00 Mn
Mar 31, 2018 291.00 Mn
Dec 31, 2017 149.00 Mn
Sep 30, 2017 207.00 Mn
Jun 30, 2017 73.00 Mn
Mar 31, 2017 71.00 Mn
Dec 31, 2016 -101.00 Mn
Sep 30, 2016 -22.00 Mn
Jun 30, 2016 -19.00 Mn
Mar 31, 2016 -48.00 Mn
Dec 31, 2015 -903.00 Mn
Sep 30, 2015 170.00 Mn
Jun 30, 2015 -739.00 Mn
Mar 31, 2015 -55.00 Mn
Dec 31, 2014 10.64 Bn
Sep 30, 2014 166.00 Mn
Jun 30, 2014 650.00 Mn
Mar 31, 2014 163.00 Mn
Dec 31, 2013 245.00 Mn
Sep 30, 2013 -172.00 Mn
Jun 30, 2013 -201.00 Mn
Mar 31, 2013 -282.00 Mn
Dec 31, 2012 -670.00 Mn
Sep 30, 2012 -200.00 Mn
Jun 30, 2012 -103.00 Mn
Mar 31, 2012 -142.00 Mn
Dec 31, 2011 -137.00 Mn
Sep 30, 2011 -66.00 Mn
Jun 30, 2011 -121.00 Mn
Mar 31, 2011 -622.00 Mn
Dec 31, 2010 -309.00 Mn
Sep 30, 2010 -1.11 Bn
Jun 30, 2010 281.00 Mn
Mar 31, 2010 -167.00 Mn
Dec 31, 2009 7.81 Bn
Sep 30, 2009 2.79 Bn
Jun 30, 2009 -3.60 Mn
Mar 31, 2009 67.20 Mn